FDA Raising Approval Bar For NSAID/PPI Combos; Endpoints Under Review
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA is considering changes to the approval process for NSAID and proton pump inhibitor combination products that may result in the agency prohibiting the use of endoscopic gastric ulcer reduction to support a gastroprotective marketing claim